Biotechnology company EpilepsyGTx has appointed Professor Dimitri Kullman as Chief Scientific Officer. 

As a Co-Founder of EpilepsyGTx, the company says Kullmann’s role as CSO will shape and execute scientific strategy, setting research priorities and overseeing the delivery of its pipeline programmes. 

EpilepsyGTx sees Kullmann as an internationally recognised leader in neuroscience, with more than three decades of pioneering research in synaptic function, work that directly underpinned the creation of EpilepsyGTx in 2021.  

Kullman is currently Professor of Neurology in the Department of Epilepsy at the University College London (UCL) Institute of Neurology and has 27 years of experience as a consultant neurologist at the National Hospital for Neurology and Neurosurgery. 

“Having been a part of EpilepsyGTx’s team since its founding, I am immensely proud of the significant progress we have made in developing novel gene therapies for refractory epilepsy over the last few years,” Kullman said. 

“The company is poised to transform the treatment of common forms of drug-resistant epilepsy with its novel gene therapies including EPY201.” 

“Dimitri’s transition to CSO marks an important milestone for EpilepsyGTx as we take our lead programme EPY201 through the clinical development process,” added Nicolas Koebel, Chief Executive Officer of EpilepsyGTx. 

“His synaptic research and extensive clinical experience were critical to the founding of EpilepsyGTx and will continue to be invaluable as we deliver on our mission of eradicating seizures in patients with focal refractory epilepsy.”